{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:45:39Z","timestamp":1780767939749,"version":"3.54.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Men with erectile dysfunction (ED) are typically older and have one or more underlying cardiovascular conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To determine the efficacy and safety of a new orodispersible tablet (ODT) formulation of vardenafil for the treatment of ED, and whether age, or the presence of underlying conditions affects treatment outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is an integrated analysis of data from two phase III, double-blind, multicenter, randomized, parallel-group, placebo-controlled studies that compared 10\u2003mg on-demand vardenafil ODT with placebo in a general population of men with ED, stratified so that approximately 50% of patients were aged \u226565 years. Results were reported by age (&amp;lt;65 vs. \u226565 years) and presence\/absence of diabetes, dyslipidemia, or hypertension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Primary measures were the erectile function domain of the International Index of Erectile Function (IIEF-EF) and Sexual Encounter Profile questions 2 (SEP2) and 3 (SEP3).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 701 men randomized (51% aged \u226565 years), 686 were included in the intent-to-treat population (placebo, n\u2003=\u2003334; vardenafil ODT, n\u2003=\u2003352). Vardenafil ODT was significantly superior to placebo for all primary efficacy measures, regardless of age, baseline ED severity, or underlying condition (P\u2003&amp;lt;\u20030.0001 for vardenafil vs. placebo for each endpoint). IIEF-EF scores and SEP2\/3 success rates in older patients and men with underlying conditions were not significantly different to those of younger patients or men without underlying conditions. Adverse events (AEs) were mostly mild to moderate in severity, occurring with higher incidence in the vardenafil vs. placebo group. The most frequently reported drug-related AEs in the vardenafil group were headache, flushing, nasal congestion, dizziness, and dyspepsia, consistent with the known safety profile of phosphodiesterase type 5 inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Vardenafil ODT significantly improves erectile function in men with ED regardless of age, baseline ED severity, or underlying condition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2010.02005.x","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T16:06:36Z","timestamp":1283270796000},"page":"261-271","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials"],"prefix":"10.1093","volume":"8","author":[{"given":"Herbert","family":"Sperling","sequence":"first","affiliation":[{"name":"Kliniken Maria Hilf GmbH , M\u00f6nchengladbach , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gittelman","sequence":"additional","affiliation":[{"name":"Department of Urology, South Florida Medical Research , Aventura, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Norenberg","sequence":"additional","affiliation":[{"name":"Bayer HealthCare AG, Bayer Schering Pharma , Wuppertal , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Ulbrich","sequence":"additional","affiliation":[{"name":"Bayer Vital GmbH , Leverkusen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Ewald","sequence":"additional","affiliation":[{"name":"Bayer HealthCare AG, Bayer Schering Pharma , Wuppertal , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"2024032521471812700_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH Consensus Development Panel on Impotence","volume":"270","author":"NIH Consensus Conference","year":"1993","journal-title":"JAMA"},{"key":"2024032521471812700_bb0015","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: Prevalence and predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"2024032521471812700_bb0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1185\/030079904125003467","article-title":"The multinational Men\u2019s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population","volume":"20","author":"Rosen","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"2024032521471812700_bb0025","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1743-6109.2009.01601.x","article-title":"Age-related changes in general and sexual health in middle-aged and older men: Results from the European Male Ageing Study (EMAS)","volume":"7","author":"Corona","year":"2010","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2024032521471812700_bb0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0022-5347(05)65986-1","article-title":"Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina Study","volume":"166","author":"Martin-Morales","year":"2001","journal-title":"J Urol"},{"key":"2024032521471812700_bb0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ucl.2005.08.004","article-title":"Epidemiology of erectile dysfunction: The role of medical comorbidities and lifestyle factors","volume":"32","author":"Rosen","year":"2005","journal-title":"Urol Clin North Am"},{"key":"2024032521471812700_bb0045","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1743-6109.2007.00745.x","article-title":"Prevalence, severity, and risk factors for erectile dysfunction in a representative sample of 3,548 Portuguese men aged 40 to 69 years attending primary healthcare centers: Results of the Portuguese erectile dysfunction study","volume":"5","author":"Teles","year":"2008","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.ijir.3900905","article-title":"Prevalence of erectile dysfunction: A systematic review of population-based studies","volume":"14","author":"Prins","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024032521471812700_bb0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4065\/84.2.108","article-title":"A population-based, longitudinal study of erectile dysfunction and future coronary artery disease","volume":"84","author":"Inman","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2024032521471812700_bb0060","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ijir.2008.20","article-title":"Erectile dysfunction as a predictor of cardiovascular disease","volume":"20","author":"Kloner","year":"2008","journal-title":"Int J Impot Res"},{"key":"2024032521471812700_bb0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1743-6109.2005.00084.x","article-title":"Association between erectile dysfunction and coronary artery disease: A case report study","volume":"2","author":"Montorsi","year":"2005","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0070","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1001\/jama.294.23.2996","article-title":"Erectile dysfunction and subsequent cardiovascular disease","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"key":"2024032521471812700_bb0075","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2605.2008.00951.x","article-title":"Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases","volume":"32","author":"Corona","year":"2009","journal-title":"Int J Androl"},{"key":"2024032521471812700_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/pmed.2000.0643","article-title":"Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study","volume":"30","author":"Feldman","year":"2000","journal-title":"Prev Med"},{"key":"2024032521471812700_bb0085","first-page":"19","article-title":"Prevalence of cardiovascular risk factors in erectile dysfunction","volume":"5","author":"Walczak","year":"2002","journal-title":"J Gend Specif Med"},{"key":"2024032521471812700_bb0090","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.urology.2004.08.059","article-title":"Prevalence of erectile dysfunction among 7,689 patients with diabetes or hypertension, or both","volume":"64","author":"Giuliano","year":"2004","journal-title":"Urology"},{"key":"2024032521471812700_bb0095","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00251005","article-title":"The prevalence of diabetic impotence","volume":"18","author":"McCulloch","year":"1980","journal-title":"Diabetologia"},{"key":"2024032521471812700_bb0100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.diabres.2005.02.018","article-title":"Prevalence and risk factors for erectile dysfunction in Japanese diabetics","volume":"70","author":"Sasaki","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"2024032521471812700_bb0105","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2337\/diacare.26.4.1093","article-title":"Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database","volume":"26","author":"Penson","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032521471812700_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0302-2838(03)00306-3","article-title":"Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk","volume":"44","author":"Roumeguere","year":"2003","journal-title":"Eur Urol"},{"key":"2024032521471812700_bb0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.ju.0000162050.84946.86","article-title":"Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study","volume":"174","author":"Sun","year":"2005","journal-title":"J Urol"},{"key":"2024032521471812700_bb0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.ju.0000164463.19239.19","article-title":"Chapter 1: The management of erectile dysfunction: An AUA update","volume":"174","author":"Montague","year":"2005","journal-title":"J Urol"},{"key":"2024032521471812700_bb0125","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.eururo.2006.01.028","article-title":"EAU guidelines on erectile dysfunction: An update","volume":"49","author":"Wespes","year":"2006","journal-title":"Eur Urol"},{"key":"2024032521471812700_bb0130","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1743-6109.2006.00383.x","article-title":"Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction\u2014Results from 30,010 U.S. patients","volume":"4","author":"Cheng","year":"2007","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1743-6109.2009.01547.x","article-title":"Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications","volume":"7","author":"Eardley","year":"2010","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0140","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1743-6109.2006.00329.x","article-title":"Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): A randomized, double-blind, placebo-controlled trial in PDE5 inhibitor\u2014naive men with ED and their partners","volume":"3","author":"Edwards","year":"2006","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1743-6109.2005.00119.x","article-title":"Improving the sexual quality of life of couples affected by erectile dysfunction: A double-blind, randomized, placebo-controlled trial of vardenafil","volume":"2","author":"Fisher","year":"2005","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1212\/01.wnl.0000194260.43583.32","article-title":"Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury","volume":"66","author":"Giuliano","year":"2006","journal-title":"Neurology"},{"key":"2024032521471812700_bb0155","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.eururo.2004.01.014","article-title":"The efficacy and safety of flexible-dose vardenafil (Levitra\u00ae) in a broad population of European men","volume":"45","author":"Hatzichristou","year":"2004","journal-title":"Eur Urol"},{"key":"2024032521471812700_bb0160","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1939-4640.2002.tb02332.x","article-title":"Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Hellstrom","year":"2002","journal-title":"J Androl"},{"key":"2024032521471812700_bb0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1464-410X.2007.06900.x","article-title":"Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners","volume":"100","author":"Ralph","year":"2007","journal-title":"BJU Int"},{"key":"2024032521471812700_bb0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1368-5031.2004.00128.x","article-title":"Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction","volume":"58","author":"Stief","year":"2004","journal-title":"Int J Clin Pract"},{"key":"2024032521471812700_bb0175","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1742-1241.2010.02358.x","article-title":"The POTENT II randomised trial: Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction","volume":"64","author":"Gittelman","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2024032521471812700_bb0180","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1743-6109.2010.01806.x","article-title":"The POTENT I randomized trial: Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction","volume":"7","author":"Sperling","year":"2010","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0185","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032521471812700_bb0190","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1743-6109.2005.00150.x","article-title":"Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives","volume":"2","author":"van Ahlen","year":"2005","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0195","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2004.04819.x","article-title":"The efficacy and safety of tadalafil: An update","volume":"93","author":"Carson","year":"2004","journal-title":"BJU Int"},{"key":"2024032521471812700_bb0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2009.02254.x","article-title":"Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database","volume":"64","author":"Giuliano","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2024032521471812700_bb0205","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0090-4295(03)00491-6","article-title":"Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"key":"2024032521471812700_bb0210","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/BF03349261","article-title":"The use of phosphodiesterase 5 inhibitors with concomitant medications","volume":"31","author":"Corona","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"2024032521471812700_bb0215","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1743-6109.2008.00820.x","article-title":"Vardenafil in men with stable statin therapy and dyslipidemia","volume":"5","author":"Miner","year":"2008","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0220","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4065\/80.10.1291","article-title":"Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled study","volume":"80","author":"Valiquette","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"2024032521471812700_bb0225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1743-6109.2006.00295.x","article-title":"Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction","volume":"3","author":"Ziegler","year":"2006","journal-title":"J Sex Med"},{"key":"2024032521471812700_bb0230","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1526-4610.2007.00805.x","article-title":"Patient preference for triptan formulations: A prospective study with zolmitriptan","volume":"47","author":"Dowson","year":"2007","journal-title":"Headache"},{"issue":"3","key":"2024032521471812700_bb0235","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1185\/030079905X46287","article-title":"Part III: The convenience of, and patient preference for, zolmitriptan orally disintegrating tablet","volume":"21","author":"Dowson","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2024032521471812700_bb0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1098-3597(05)80049-3","article-title":"Patient preferences in treatment of erectile dysfunction: The continuing importance of patient education","volume":"7","author":"Hackett","year":"2005","journal-title":"Clin Cornerstone"},{"key":"2024032521471812700_bb0245","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/S1520-765X(02)90045-3","article-title":"Moderators\u2019 introduction","volume":"4","author":"Jackson","year":"2002","journal-title":"Eur Heart J Suppl"},{"key":"2024032521471812700_bb0250","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1464-410X.2008.08267.x","article-title":"Tadalafil and vardenafil vs sildenafil: A review of patient-preference studies","volume":"103","author":"Mirone","year":"2009","journal-title":"BJU Int"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515332379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515332379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/1\/261\/47244981\/jsm_8_1_261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/8\/1\/261\/47244981\/jsm_8_1_261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:57:36Z","timestamp":1711403856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/8\/1\/261\/6843879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,1]]},"published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2010.02005.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,1]]},"published":{"date-parts":[[2011,1,1]]}}}